These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 37848945)

  • 1. Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study.
    Adams JW; Duprey M; Khan S; Cance J; Rice DP; Bobashev G
    Harm Reduct J; 2023 Oct; 20(1):150. PubMed ID: 37848945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs.
    Adams JW; Savinkina A; Fox A; Behrends CN; Madushani RWMA; Wang J; Chatterjee A; Walley AY; Barocas JA; Linas BP
    Addiction; 2022 Oct; 117(10):2635-2648. PubMed ID: 35315148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public Health Interventions and Overdose-Related Outcomes Among Persons With Opioid Use Disorder.
    Nataraj N; Rikard SM; Zhang K; Jiang X; Guy GP; Rice K; Mattson CL; Gladden RM; Mustaquim DM; Illg ZN; Seth P; Noonan RK; Losby JL
    JAMA Netw Open; 2024 Apr; 7(4):e244617. PubMed ID: 38568691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scope of, Motivations for, and Outcomes Associated with Buprenorphine Diversion in the United States: A Scoping Review.
    Rubel SK; Eisenstat M; Wolff J; Calevski M; Mital S
    Subst Use Misuse; 2023; 58(5):685-697. PubMed ID: 36803159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
    Gomes T; McCormack D; Bozinoff N; Tadrous M; Antoniou T; Munro C; Campbell T; Paterson JM; Mamdani M; Sproule B
    Addiction; 2022 Jul; 117(7):1972-1981. PubMed ID: 35257434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simulating the Simultaneous Impact of Medication for Opioid Use Disorder and Naloxone on Opioid Overdose Death in Eight New York Counties.
    Cerdá M; Hamilton AD; Hyder A; Rutherford C; Bobashev G; Epstein JM; Hatna E; Krawczyk N; El-Bassel N; Feaster DJ; Keyes KM
    Epidemiology; 2024 May; 35(3):418-429. PubMed ID: 38372618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
    Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
    Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper.
    Bozinoff N; Men S; Kurdyak P; Selby P; Gomes T
    JAMA Netw Open; 2022 Sep; 5(9):e2234168. PubMed ID: 36173629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US.
    Ballreich J; Mansour O; Hu E; Chingcuanco F; Pollack HA; Dowdy DW; Alexander GC
    JAMA Netw Open; 2020 Nov; 3(11):e2023677. PubMed ID: 33146732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of reductions in opioid prescribing on opioid use disorder and fatal overdose in the United States: a dynamic Markov model.
    Alexander GC; Ballreich J; Mansour O; Dowdy DW
    Addiction; 2022 Apr; 117(4):969-976. PubMed ID: 34590369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicaid Prescription Cap Policies: Another Structural Barrier to Medication for Opioid Use Disorder.
    Hughto JMW; Moyo P; Green TC
    J Addict Med; 2022 Nov-Dec 01; 16(6):616-618. PubMed ID: 35245915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Illicit use of opioid substitution drugs: prevalence, user characteristics, and the association with non-fatal overdoses.
    Bretteville-Jensen AL; Lillehagen M; Gjersing L; Andreas JB
    Drug Alcohol Depend; 2015 Feb; 147():89-96. PubMed ID: 25543167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine.
    Silverstein SM; Daniulaityte R; Miller SC; Martins SS; Carlson RG
    Drug Alcohol Depend; 2020 May; 210():107958. PubMed ID: 32203863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Treatments for Opioid Use Disorder.
    Fairley M; Humphreys K; Joyce VR; Bounthavong M; Trafton J; Combs A; Oliva EM; Goldhaber-Fiebert JD; Asch SM; Brandeau ML; Owens DK
    JAMA Psychiatry; 2021 Jul; 78(7):767-777. PubMed ID: 33787832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in opioid use disorder and overdose among opioid-naive individuals receiving an opioid prescription in Massachusetts from 2011 to 2014.
    Burke LG; Zhou X; Boyle KL; Orav EJ; Bernson D; Hood ME; Land T; Bharel M; Frakt AB
    Addiction; 2020 Mar; 115(3):493-504. PubMed ID: 31691390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018.
    Lee B; Zhao W; Yang KC; Ahn YY; Perry BL
    JAMA Netw Open; 2021 Feb; 4(2):e2036687. PubMed ID: 33576816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health Care Utilization of Opioid Overdose Decedents with No Opioid Analgesic Prescription History.
    Abbasi AB; Salisbury-Afshar E; Jovanov D; Berberet C; Arunkumar P; Aks SE; Layden JE; Pho MT
    J Urban Health; 2019 Feb; 96(1):38-48. PubMed ID: 30607879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
    Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
    PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A practical review of buprenorphine utilization for the emergency physician in the era of decreased prescribing restrictions.
    Pourmand A; Beisenova K; Shukur N; Tebo C; Mortimer N; Mazer-Amirshahi M
    Am J Emerg Med; 2021 Oct; 48():316-322. PubMed ID: 34274576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine Treatment Intake and Critical Encounters following a Nonfatal Opioid Overdose.
    Victor GA; Bailey K; Ray B
    Subst Use Misuse; 2021; 56(7):988-996. PubMed ID: 33749520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.